Literature DB >> 10822130

Establishment of a new human pancreatic cancer cell line, NOR-P1, with high angiogenic activity and metastatic potential.

N Sato1, K Mizumoto, K Beppu, N Maehara, M Kusumoto, T Nabae, T Morisaki, M Katano, M Tanaka.   

Abstract

We present here a new cell line, NOR-P1, established from a metastatic subcutaneous tumor of a patient with pancreatic cancer. The cells show rapid growth in culture with a doubling time of 16 h and high migration activity. Genetic and molecular analyses revealed high telomerase activity and a mutation in the K-ras oncogene. Of particular interest, the cells express markedly elevated mRNA levels of angiogenic factors, vascular endothelial growth factor and platelet-derived growth factor, as well as other tumor growth-related factors. Subcutaneous transplantation of the NOR-P1 cells into nude mice formed solid, hemorrhagic tumors which were histologically diagnosed as adenocarcinoma with dense blood vessels and severe extravasation of blood. Furthermore, when NOR-P1 cell suspension was injected directly into the pancreas of nude mice, the cells grew rapidly to form intra-pancreatic tumors associated with liver metastases and peritoneal dissemination that resulted in cachexia and subsequent death. These properties suggest that NOR-P1 is an aggressive pancreatic cancer cell line with a high metastatic potential and may serve as a useful experimental model for studying tumor angiogenesis and metastasis of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10822130     DOI: 10.1016/s0304-3835(00)00421-3

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  Establishment and characterization of SUIT-58 pancreas cancer cell line and its subline S58-SF adapted to serum-free condition derived from metastatic liver tumor.

Authors:  Nobuyasu Takahashi; Fumiyo Aoyama; Jiro Ohuchida; Naoki Sameshima; Yujiro Asada; Akira Sawaguchi
Journal:  Hum Cell       Date:  2015-07-04       Impact factor: 4.174

2.  Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Takao Sugiyama; Shigenori Yamamoto; Makoto Sueishi; Takanobu Yoshida
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

3.  Prognostic and functional role of hyaluronan-binding protein 1 in pancreatic ductal adenocarcinoma.

Authors:  Yasuhiro Adachi; Norihiro Sato; Takuya Oba; Takao Amaike; Yuzan Kudo; Shiro Kohi; Toshiyuki Nakayama; Keiji Hirata
Journal:  Oncol Lett       Date:  2022-05-23       Impact factor: 3.111

4.  Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs.

Authors:  H Zhang; T Morisaki; H Matsunaga; N Sato; A Uchiyama; K Hashizume; F Nagumo; J Tadano; M Katano
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  Prospectively isolated cancer-associated CD10(+) fibroblasts have stronger interactions with CD133(+) colon cancer cells than with CD133(-) cancer cells.

Authors:  Lin Cui; Kenoki Ohuchida; Kazuhiro Mizumoto; Taiki Moriyama; Manabu Onimaru; Kohei Nakata; Toshinaga Nabae; Takashi Ueki; Norihiro Sato; Yohei Tominaga; Masao Tanaka
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

6.  Development and characterization of a cancer cachexia model employing a rare human duodenal neuroendocrine carcinoma-originating cell line.

Authors:  Kazuyoshi Yanagihara; Takanori Kubo; Yuki Iino; Keichiro Mihara; Chie Morimoto; Toshio Seyama; Takeshi Kuwata; Atsushi Ochiai; Hiroshi Yokozaki
Journal:  Oncotarget       Date:  2019-03-29

7.  Development and Biological Analysis of a Novel Orthotopic Peritoneal Dissemination Mouse Model Generated Using a Pancreatic Ductal Adenocarcinoma Cell Line.

Authors:  Kazuyoshi Yanagihara; Takanori Kubo; Keichiro Mihara; Takeshi Kuwata; Atsushi Ochiai; Toshio Seyama; Hiroshi Yokozaki
Journal:  Pancreas       Date:  2019-03       Impact factor: 3.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.